NO20101375L - Stabile, flytende formuleringer av antiinfektive midler og justerte doseringsregimer for det antiinfektive middel - Google Patents

Stabile, flytende formuleringer av antiinfektive midler og justerte doseringsregimer for det antiinfektive middel

Info

Publication number
NO20101375L
NO20101375L NO20101375A NO20101375A NO20101375L NO 20101375 L NO20101375 L NO 20101375L NO 20101375 A NO20101375 A NO 20101375A NO 20101375 A NO20101375 A NO 20101375A NO 20101375 L NO20101375 L NO 20101375L
Authority
NO
Norway
Prior art keywords
infective
stable
liquid formulations
dosage regimens
infective agent
Prior art date
Application number
NO20101375A
Other languages
English (en)
Norwegian (no)
Inventor
Gary Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20101375L publication Critical patent/NO20101375L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20101375A 2008-03-04 2010-10-04 Stabile, flytende formuleringer av antiinfektive midler og justerte doseringsregimer for det antiinfektive middel NO20101375L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3359808P 2008-03-04 2008-03-04
PCT/US2009/035794 WO2009111422A2 (fr) 2008-03-04 2009-03-03 Formulations liquides stables d’agents anti-infectieux et régimes posologiques réglés des agents anti-infectieux

Publications (1)

Publication Number Publication Date
NO20101375L true NO20101375L (no) 2010-10-04

Family

ID=41054292

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20101375A NO20101375L (no) 2008-03-04 2010-10-04 Stabile, flytende formuleringer av antiinfektive midler og justerte doseringsregimer for det antiinfektive middel

Country Status (12)

Country Link
US (2) US20090227554A1 (fr)
EP (1) EP2257159A4 (fr)
JP (1) JP2011514902A (fr)
KR (1) KR20100137439A (fr)
AU (1) AU2009222020A1 (fr)
CA (1) CA2713989A1 (fr)
IL (1) IL207968A0 (fr)
MX (1) MX2010009628A (fr)
NO (1) NO20101375L (fr)
TW (1) TW200940552A (fr)
WO (1) WO2009111422A2 (fr)
ZA (1) ZA201005495B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970338A1 (fr) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Forme cristalline d'un inhibiteur de bêta-lactamase
AU2014227660B2 (en) 2013-03-15 2014-11-06 Merck Sharp & Dohme Llc Ceftolozane antibiotic compositions
US20140274997A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Cephalosporin pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2015051101A1 (fr) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. Sel picoline inhibiteur de b-lactamase
WO2017168395A1 (fr) * 2016-03-31 2017-10-05 Wockhardt Limited Compositions antibactériennes et méthodes
AU2017242134B2 (en) * 2016-03-31 2022-12-01 Wockhardt Limited Antibacterial compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510690A (en) * 1998-09-25 2002-10-25 Cubist Pharm Inc Methods for administration of antibiotics
JP2002543434A (ja) * 1999-04-29 2002-12-17 デイド マイクロスキャン インコーポレーテッド 迅速な抗菌物質感受性アッセイと微生物同定を組み合わせたシステム
US6884791B2 (en) * 1999-07-06 2005-04-26 Methylgene, Inc. Inhibitors of β-lactamase
US6482982B1 (en) * 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
CA2458926A1 (fr) * 2001-09-13 2003-03-13 Genesoft Pharmaceuticals, Inc. Methodes pour traiter une infection par une bacterie pharmacoresistante
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US20030152515A1 (en) * 2002-02-06 2003-08-14 Ren-Jin Lee Method for estimating effective regimens and patient survival rates of antibiotic treatments for fatal infectious diseases
AU2003242404A1 (en) * 2002-06-13 2003-12-31 Hououdou Co., Ltd. Antibacterial agent and antibacterial composition
WO2004000323A1 (fr) * 2002-06-21 2003-12-31 Shionogi & Co., Ltd. Composition medicinale a base de compose cepheme destinee a une injection
US7244712B2 (en) * 2003-03-14 2007-07-17 President And Fellows Of Harvard College Aminoglycoside antibiotics and methods of using same
US20060018966A1 (en) * 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
US20070238717A1 (en) * 2003-10-21 2007-10-11 Johns Hopkins University Neuroprotection with Beta-Lactam Compounds
CA2559208A1 (fr) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Utilisation et administration d'inhibiteurs de pompe d'efflux de bacteries
WO2005094800A2 (fr) * 2004-03-31 2005-10-13 Lupin Ltd. Composition de cefepime co-precipite et procede de preparation correspondant
EP1656930A1 (fr) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Formulation lyophilisée stabilisée pour des dérivés des céphalosporines
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
EP3067047B1 (fr) * 2005-12-08 2022-04-20 Insmed Incorporated Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires
CA2641064C (fr) * 2006-03-23 2017-03-07 Agriculture Victoria Services Pty Limited Proteine antimicrobienne
US20090048160A1 (en) * 2007-08-17 2009-02-19 Bannerman Douglas D Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates
WO2009059379A1 (fr) * 2007-11-07 2009-05-14 Dynamic Microbials Limited Compositions et formulations antimicrobiennes et leurs utilisations

Also Published As

Publication number Publication date
AU2009222020A1 (en) 2009-09-11
WO2009111422A3 (fr) 2009-12-30
TW200940552A (en) 2009-10-01
CA2713989A1 (fr) 2009-09-11
IL207968A0 (en) 2010-12-30
EP2257159A2 (fr) 2010-12-08
WO2009111422A9 (fr) 2010-04-15
MX2010009628A (es) 2010-09-28
ZA201005495B (en) 2011-04-28
KR20100137439A (ko) 2010-12-30
US20120115836A1 (en) 2012-05-10
US20090227554A1 (en) 2009-09-10
JP2011514902A (ja) 2011-05-12
WO2009111422A2 (fr) 2009-09-11
EP2257159A4 (fr) 2011-05-11

Similar Documents

Publication Publication Date Title
NO20101375L (no) Stabile, flytende formuleringer av antiinfektive midler og justerte doseringsregimer for det antiinfektive middel
MA33806B1 (fr) Inhibiteurs du virus de l'hepatite c
MY204500A (en) Dosing regimen associated with long acting injectable paliperidone esters
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
UY31958A (es) Nucleosidos y nucleotidos bicilicos como agentes terapeuticos
ATE489048T1 (de) Vorrichtung für kombinierte behandlung
EA201170521A1 (ru) Новые соединения
MX2010002316A (es) Derivados tetraciclicos de indol y su uso para el tratamiento o prevencion de infecciones virales.
MX2011007195A (es) Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
GEP20146134B (en) Inhibitors of hepatitis c virus replication
EA201100390A1 (ru) Соединения для лечения гепатита с
IN2014DN09678A (fr)
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
NI200900071A (es) Compuestos de pirozolina y su uso y composiciones farmacéuticas. pc 33496a.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
MX2011013296A (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
ITFI20110166A1 (it) Nuovi fotosensibilizzanti ad uso terapeutico.
NO20091580L (no) Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin
DK1610787T3 (da) Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme
EA201390925A1 (ru) Производные санглиферина и способы их получения
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.
MX2009006311A (es) Terapia de combinacion para tratar infecciones de hepatitis c.
PA8805901A1 (es) Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) para la profilaxis y el tratamiento de la aterosclerosis
WO2008106074A3 (fr) Méthodes de traitement d'une infection

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application